survival and toxicity were analyzed. In RT concurrently PP arm 50 mg/ m 2 paclitaxel and 20 mg/m 2 cisplatin or carboplatin AUC 2; in PD arm 20 mg/m 2 dosetaxel and 20 mg/m 2 cisplatin applied. Radiotheraphy applied as weekly 5 fraction/ 60-66 Gy. Treatment response classified progression and clinically responsive which consist of stable response (SR), complete response(CR) and partial response(PR). Result: One hundred thirty one (92,3%) patients were man and median age was 62 (25-79). Histologic subtype was squamous cell carcinoma in 77 (54.2%) patients. At diagnosis 53 patients (37,3%) were stage IIIA, 89 (62,7%) patients were stage IIIB and IIIC. There were 102 patients in DP arm whereas 40 patients were in PP arm. Age, gender, stage and histologic subtypes were similar in both groups.There were no statistically significant in clinically response rates between two group (PD 96,1% vs PP 90% , p ¼ 0.15) . Median overall survival (OS) was higher in PP arm than PD arm ( 29 vs 14,4 months ,p¼0,018). Progression free survival (PFS) were same in both arms (15,6 vs 15,4 months p¼0,522).There were no statistically significant in mucositis and eosophitis( 90% vs 80 %, p¼0,418) and vomiting (10% vs 8,8%, p¼0,931) in both arms. In PP arm neutropenia (p¼0,000) and thrombocytopenia rates were higher (p¼0,021). Pulmonary toxicity (p¼0,053) and nausea (p¼0,056) was higher in PP arm, which is closed to statistical significance. Although deaths due to treatment toxicity were not detected ,progression and other reason related death were more common in PD arm (p<0,001). Conclusion: In our study, despite clinical response and PFS were same in both radiotheraphy concurrent regimens in locally advanced unresectable NSCLC, OS was higher in PP arm. There are few study compared this two arms, which show no OS differences. Although it must be supported by prospective studies, OS is beter in PP arm than PD arm.